Novel treatment progress of IgA nephropathy
10.3760/cma.j.cn441217-20241210-01222
- VernacularTitle:IgA肾病诊疗新进展
- Author:
Naya HUANG
1
;
Qiong WEN
1
;
Yanping FAN
1
;
Wei CHEN
1
Author Information
1. 中山大学附属第一医院肾内科 卫生健康委肾脏病重点实验室 广东省肾脏病重点实验室，广州510080
- Publication Type:Journal Article
- Keywords:
Glomerulonephritis, IgA;
Therapy;
B-lymphocytes;
Galactose-deficient IgA1;
B cell modulators;
Proliferation-inducing ligands;
TNF family B cell activators;
C
- From:
Chinese Journal of Nephrology
2025;41(3):213-219
- CountryChina
- Language:Chinese
-
Abstract:
IgA nephropathy is the most common primary glomerular disease globally, with the highest incidence in the Asian region, and has a high risk of progressing to end-stage renal disease even in patients with low proteinuria. The treatment paradigm for IgA nephropathy has undergone significant changes. Treatment should aim to reduce pathogenic IgA and IgA immune complex formation, including intestinal mucosal B cell immune modulators such as budesonide enteric-coated capsules, targeted APRIL and BAFF agents, and B cell depletors; it should also manage glomerular inflammation, including corticosteroids, mycophenolate mofetil, hydroxychloroquine, and targeting complement therapy; and it should manage general responses to nephron loss, including lifestyle interventions, renin-angiotensin system inhibitors, sodium-glucose cotransporter-2 inhibitors, and endothelin receptor antagonists. This article provides a comprehensive overview of the treatment paradigm and drug advancements for IgA nephropathy, aiming to provide more rational treatment options for IgA nephropathy patients and improve their outcomes.
